- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharvaris NV (PHVS)
The Pharvaris NV share price today is 34.94, view NASDAQ PHVS stock exchange data. Track the latest Pharvaris NV share price with real-time updates on PHVS stock performance including market cap, day range, 52-week range and dividend yield. Access PHVS charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.24
35.07
52 wk Range
19.12
36.60
PHVS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.2435.07
52 wk Range
19.1236.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHVS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
47.28
Upside
+35.32%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 144 Pharvaris N.V. For: 25 June
- Investing.com
- Pharvaris BV receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 Pharvaris N.V. For: 25 June
- Investing.com
- Form 144 Pharvaris N.V. For: 13 July
- Investing.com
- Pharvaris BV receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 Pharvaris N.V. For: 13 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 47.28
(+35.32% Upside)
Pharvaris NV SWOT Analysis
Promising HAE Drug | Pharvaris's deucrictibant shows superior efficacy in resolving HAE attacks, positioning it as a potential best-in-class oral treatment for both acute and prophylactic use. |
Financial Fortitude | With $397 million in cash, Pharvaris has a two-year runway to advance clinical trials, despite higher-than-expected R&D expenses and operating losses. |
Market Opportunity | Explore Pharvaris's potential to capture a significant share of the $2+ billion HAE market, with peak sales estimates of $500M for acute and $1.5B for prophylactic use. |
Analyst Outlook | JMP Securities maintains a "Market Outperform" rating with a $50 price target, reflecting confidence in deucrictibant's potential and Pharvaris's strong market positioning. |
Earnings
Latest Release
12-05-2026
EPS / Forecast
-0.59 / -0.71
Revenue / Forecast
-- / --
Compare PHVS to Peers and Sector
Metrics to compare | PHVS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHVSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.7x | −8.3x | −0.4x | |
PEG Ratio | −3.98 | −0.03 | 0.00 | |
Price/Book | 9.0x | 6.4x | 2.6x | |
Price / LTM Sales | - | 16.7x | 3.0x | |
Upside (Analyst Target) | 32.2% | 79.2% | 53.5% | |
Fair Value Upside | Unlock | 10.9% | 9.0% | Unlock |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Pharvaris NV (PHVS) Share Price Today?
The Pharvaris NV share price today is 34.94.
What is the current Pharvaris NV (PHVS) share price and day range?
As of 19-07-2026, the Pharvaris NV share price is 34.94, with a previous close of 33.66. The share price has ranged from 33.24 to 35.07 today, while the 52-week range spans from 19.12 to 36.60.
What Is the Pharvaris NV Market Cap?
As of today, Pharvaris NV market cap is 2.44B.
What Is the Pharvaris NV (PHVS) Share Price Target?
The average 12-month share price target for Pharvaris NV is 47.28, with a high estimate of 74.13520933 and a low estimate of 32.23747426. 13 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +35.32% Upside potential.
What Is Pharvaris NV's Earnings Per Share (TTM)?
The Pharvaris NV EPS (TTM) is -2.72.
When Is the Next Pharvaris NV Earnings Date?
Pharvaris NV will release its next earnings report on 19-08-2026.
From a Technical Analysis Perspective, Is PHVS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Pharvaris NV Trade On?
Pharvaris NV is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Pharvaris NV?
The stock symbol for Pharvaris NV is "PHVS."
How Many Times Has Pharvaris NV Stock Split?
Pharvaris NV has split 0 times.
How Many Employees Does Pharvaris NV Have?
Pharvaris NV has 134 employees.
What Is the PHVS Premarket Price?
PHVS's last pre-market stock price is 34.20. The pre-market share volume is 110.00, and the stock has changed by 0.54, or 1.60%.
What Is the PHVS After Hours Price?
PHVS's last after hours stock price is 35.06, the stock has changed by 0.12, or 0.34%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.